KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small-cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study.

N Girard, M Burotto, L G Paz-Ares, M Schenker, A Lingua, F Orlandi, J Naidoo, E K Beardsley, V Velcheti, G L Martinengo, E Felip, M Reck, A Qureshi, P Kasbekar, S Samanta, J Neely, C Garnett-Benson, L McDonald, J X Yu, M Cobo-Dols

Ann Oncol S0923-7534(26)06885-7

PMID42918419
PMCID-
DOI10.1016/j.annonc.2026.10.103
发表日期2026-10-23
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

BACKGROUND: Programmed death 1-blocking antibody, nivolumab, plus lymphocyte-activation gene 3-blocking antibody, relatlimab, is approved for advanced melanoma. We report results from Part 2 of RELATIVITY-104, the first phase II, proof-of-concept, head-to-head study to evaluate first-line nivolumab plus relatlimab plus platinum-doublet chemotherapy (PDCT) versus nivolumab plus PDCT in patients with stage IV/recurrent non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: In Part 2, patients were randomly assigned 1 : 1 to nivolumab plus relatlimab plus PDCT or nivolumab plus PDCT. The primary endpoint was objective response rate (ORR) per blinded independent central review (BICR). Secondary endpoints included progression-free survival (PFS) and duration of response (DOR) per BICR, ORR and PFS by subgroups, and safety. Exploratory analyses included overall survival (OS), biomarker, translational, and patient-reported outcomes. RESULTS: In Part 2, the primary endpoint was not met (ORR, 51.3% for nivolumab plus relatlimab plus PDCT versus 45.0% for nivolumab plus PDCT); PFS hazard ratio [HR; 90% confidence interval (CI)] was 0.89 (0.72-1.09). A trend toward improved clinical benefit was seen with nivolumab plus relatlimab plus PDCT in a subgroup of patients with programmed death ligand 1 (PD-L1) ≥1% and nonsquamous histology (ORR: 58.0% versus 39.6%; PFS: HR 0.68, 90% CI 0.46-1.01). A potential improvement in OS was observed with nivolumab plus relatlimab plus PDCT in the PD-L1 ≥1% nonsquamous subgroup (HR 0.60, 90% CI 0.38-0.94). The safety profile of nivolumab plus relatlimab plus PDCT was manageable and consistent with previous reports. CONCLUSION: In RELATIVITY-104, the addition of relatlimab to standard of care did not improve outcomes in the unselected all-randomized population. However, positive trends observed in the subgroup of patients with tumor PD-L1 ≥1% and nonsquamous NSCLC supports further investigation in these patients in the phase III RELATIVITY-1093 study.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。